Printer friendly
Acronymfinder

What does NCDEU stand for?

NCDEU stands for New Clinical Drug Evaluation Unit (National Institute of Mental Health)


This definition appears very rarely and is found in the following Acronym Finder categories:

  • Science, medicine, engineering, etc.
  • Organizations, NGOs, schools, universities, etc.

Other Resources:
We have 1 other definition for NCDEU in our Acronym Attic

Samples in periodicals archive:

AT A MEETING OF THE NEW CLINICAL DRUG EVALUATION UNIT SPONSORED BY THE NATIONAL INSTITUTE OF MENTAL HEALTH PHOENIX--The use of opioids for treating depression is limited by abuse potential, but an investigational drug is showing promise in early clinical trials by providing the benefits of opioids while counteracting the mu opioid agonism thought to contribute to abuse potential.
AT A MEETING OF THE NEW CLINICAL DRUG EVALUATION UNIT SPONSORED BY THE NATIONAL INSTITUTE OF MENTAL HEALTH PHOENIX--Estrogen exposure across the lifespan appears to be associated with risk of depression during the menopausal transition, according to findings from the Study of Women's Health Across the Nation, or SWAN.
AT A MEETING OF THE NEW CLINICAL DRUG EVALUATION UNIT SPONSORED BY THE NATIONAL INSTITUTE OF MENTAL HEALTH PHOENIX--An investigational treatment for depression exploits the benefits of opioids while counteracting the mu opioid agonism thought to contribute to abuse potential.
This finding was important because treatments for bipolar disorder, particularly some atypical antipsychotics, can increase lipid abnormalities, he said in an interview at his poster at a meeting of the New Clinical Drug Evaluation Unit sponsored by the National Institute of Mental Health.
The data will be presented at the following conferences: * Society of Biological Psychiatry Annual Convention, May 17-19 (San Diego) * American Psychiatric Association Annual Meeting, May 19-24 (San Diego) * New Clinical Drug Evaluation Unit Annual (NCDEU) Meeting, June 11-14 (Boca Raton) The abstract which has been selected for these poster presentations describes the results of a Phase I, randomized, placebo-controlled double blinded, single dose-escalation study to evaluate the safety and determine the pharmacokinetic profile of BL-1020, first in class GABA-enhanced antipsychotic for the treatment of schizophrenia.
AT A MEETING OF THE NEW CLINICAL DRUG EVALUATION UNIT SPONSORED BY THE NATIONAL INSTITUTE OF MENTAL HEALTH PHOENIX--Estrogen exposure across the lifespan generally appears to be associated with risk of depression during the menopausal transition, according to findings from the Study of Women's Health Across the Nation; or SWAN.